Gilvetmab: A Breakthrough Immunotherapy for Canine Cancer
Merck Animal Health has introduced a groundbreaking immunotherapy for canine cancer called gilvetmab. This checkpoint inhibitor specifically designed for dogs targets the PD-1 protein, reactivating.
IT 
EN 
DE 
EL 
FR 
SR 
NL 
RU 
PT 
ZH